These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. Walter CP; Bleske BE; Dorsch MP J Clin Pharm Ther; 2014 Oct; 39(5):475-84. PubMed ID: 24924286 [TBL] [Abstract][Full Text] [Related]
45. Effects of low-fat compared with high-fat diet on cardiometabolic indicators in people with overweight and obesity without overt metabolic disturbance: a systematic review and meta-analysis of randomised controlled trials. Lu M; Wan Y; Yang B; Huggins CE; Li D Br J Nutr; 2018 Jan; 119(1):96-108. PubMed ID: 29212558 [TBL] [Abstract][Full Text] [Related]
46. Weight loss interventions for chronic asthma. Adeniyi FB; Young T Cochrane Database Syst Rev; 2012 Jul; (7):CD009339. PubMed ID: 22786526 [TBL] [Abstract][Full Text] [Related]
47. The Association of Weight Loss and Cardiometabolic Outcomes in Obese Children: Systematic Review and Meta-regression. Rajjo T; Almasri J; Al Nofal A; Farah W; Alsawas M; Ahmed AT; Mohammed K; Kanwar A; Asi N; Wang Z; Prokop LJ; Murad MH J Clin Endocrinol Metab; 2016 Dec; 102(3):758-62. PubMed ID: 27603909 [TBL] [Abstract][Full Text] [Related]
48. Lorcaserin for the treatment of obesity. Redman LM; Ravussin E Drugs Today (Barc); 2010 Dec; 46(12):901-10. PubMed ID: 21589947 [TBL] [Abstract][Full Text] [Related]
49. Role of metformin for weight management in patients without type 2 diabetes. Desilets AR; Dhakal-Karki S; Dunican KC Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733 [TBL] [Abstract][Full Text] [Related]
50. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Bays HE Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803 [TBL] [Abstract][Full Text] [Related]
51. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. de Andrade Mesquita L; Fagundes Piccoli G; Richter da Natividade G; Frison Spiazzi B; Colpani V; Gerchman F Obes Rev; 2021 Mar; 22(3):e13170. PubMed ID: 33258543 [TBL] [Abstract][Full Text] [Related]
52. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Lucchetta RC; Riveros BS; Pontarolo R; Radominski RB; Otuki MF; Fernandez-Llimos F; Correr CJ Clinics (Sao Paulo); 2017 May; 72(5):317-324. PubMed ID: 28591345 [TBL] [Abstract][Full Text] [Related]
53. Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. Hurt RT; Mundi MS; Ebbert JO Diabetes Metab Syndr Obes; 2018; 11():469-478. PubMed ID: 30233224 [TBL] [Abstract][Full Text] [Related]
54. Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update. Sharma S; Aware KS; Hatware K; Patil K Mini Rev Med Chem; 2020; 20(9):768-778. PubMed ID: 30961494 [TBL] [Abstract][Full Text] [Related]
55. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis. Kuo HH; Wang KT; Lee YH; Lin PL; Liu ME; Lin CY; Liu LY J Clin Pharm Ther; 2020 Feb; 45(1):35-44. PubMed ID: 31544267 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Chan EW; He Y; Chui CS; Wong AY; Lau WC; Wong IC Obes Rev; 2013 May; 14(5):383-92. PubMed ID: 23331711 [TBL] [Abstract][Full Text] [Related]
57. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Hurren KM; Berlie HD Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982 [TBL] [Abstract][Full Text] [Related]
58. Lorcaserin: a review of its use in chronic weight management. Hoy SM Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825 [TBL] [Abstract][Full Text] [Related]